United Homes Group stock plunges after Nikki Haley, directors resign
Cassie Jung, Chief Operating Officer of Aquestive Therapeutics, Inc. (NASDAQ:AQST), sold 67,575 shares of common stock at a price of $7.01 on October 15, 2025, for a total of $473,700. The transaction comes as the company’s stock trades near its 52-week high of $7.51, having surged approximately 179% over the past six months. According to InvestingPro analysis, the stock’s RSI indicates overbought conditions.
On the same day, Jung also exercised options to acquire 25,000 shares of Aquestive Therapeutics at an exercise price of $3.1027, for a total value of $77,567. These options were granted on June 10, 2021, and were fully vested. The sales were executed under a pre-arranged Rule 10b5-1 trading plan. For deeper insights into insider trading patterns and 12+ additional ProTips, check out InvestingPro.
Following these transactions, Jung directly holds 240,771 shares of Aquestive Therapeutics. In addition, Jung indirectly owns 2,000 shares through a spouse. The total stake represents a significant position in the company, which currently maintains a market capitalization of $842 million.
In other recent news, Aquestive Therapeutics has received two new patents for its Anaphylm dibutepinephrine sublingual film, extending its exclusivity until at least 2037. This development follows the United States Patent and Trademark Office’s decision to issue patents covering the proprietary composition of the oral treatment designed for severe allergic reactions. The company also announced that the U.S. Food and Drug Administration will not require an advisory committee meeting for Anaphylm, keeping the regulatory decision date on track for January 31, 2026. In response to these developments, Citizens raised its price target on Aquestive Therapeutics to $12.00 from $9.00, maintaining a Market Outperform rating. Additionally, Piper Sandler reiterated its Overweight rating and $5.00 price target after receiving positive feedback from allergists on Anaphylm. Cantor Fitzgerald also reaffirmed its Overweight rating with a $15.00 price target, citing potential market shifts toward needle-less epinephrine delivery as a significant opportunity for Aquestive. These developments highlight the company’s ongoing efforts and the interest in its innovative treatment options.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.